Behavioral Economics
The Hidden Forces of Behavioral Economics
Patients and clinicians decide to use or not to use products and brands for reasons that are not always rational. Efficacy and clinical data are often only casual factors in the choice of medications and pharmaceutical brands. In fact, an overwhelming body of evidence confirms patients and physicians alike often behave "irrationally", writes Daryl Travis ...Read more
Commercialization
The 3S Framework for Post-Deal Growth
Alex Chang and colleagues discuss how the “3S” framework— science, synergy, and survival — can harness the collaborative energies of each partner in a way that maximizes the overall, long-term value of the transaction ...Read more
Emerging Markets
Cuba: An Untapped Market?
If you're like us at PharmExec, you will have read the news of potentially thawing US/Cuban relations, and you might have wondered: how long before the flag of Cuba graces the Hall of nations at BIO International Convention? ...Read more
learn more about how to leverage Data and Analytics to enhance Copay Program Performance with this White Paper and Case Study:  Learn more
Europe
The EC’s New Competition Commissioner: Implications for Pharma?
What attitude will the new European commissioner for competition, Margrethe Vestager, adopt toward the pharma industry? The personalities of commissioners should have little influence over the way they conduct business, but, writes Reflector, the very nature of competition law can lend itself to subjective judgments ...Read more
Forecast
What’s Ahead for 2015? Pharm Exec’s Annual Industry Outlook
Following a year where a phenomenal cure was met by pricing outrage, the march of new products and promising immunotherapy cancer combos will continue in 2015. As pharma and tech jell, how will the industry live up to its value supposition while pricing and profiting in the developed and developing worlds? ...Read more
| 
